Companies · COO
Cooper Companies
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Oct 27, 2026
Cooper Companies CEO Albert White resigns; Board appoints STERIS veteran Walter Rosebrough as Executive Chair pending permanent CEO search.
Albert White's departure as President and CEO of Cooper Companies marks a significant leadership transition driven by board-assessed performance shortfalls. Walter Rosebrough, CEO Emeritus of STERIS with 40 years of medical device experience, assumes interim Executive Chair with day-to-day operational oversight while Russell Reynolds conducts a permanent CEO search. The Board is simultaneously refreshing its composition—adding Johnson & Johnson veteran Shlomo Nachman and reducing board size to seven members—signaling structural governance reform alongside leadership change.
Tone: cautiousRevenue
$4.1B
COO 10-K · FY 2025
Employees
15,000
Revenue FY2024
$3.9B
Headquarters
San Ramon, CA
Profile
COO 10-K Item 1 · Dec 5, 2025The Cooper Companies is a global medical device company operating through two segments: CooperVision, which manufactures and markets soft contact lenses including myopia management products, and CooperSurgical, which offers fertility and women's health products and services. The company sells in over 130 countries and reaches more than fifty million patients annually. Its portfolio spans single-use, two-week, and monthly contact lenses as well as IVF consumables, donor gametes, cryostorage, and contraception.
Read filing description ↓ Collapse description ↑
The Cooper Companies, Inc. is a leading global medical device company focused on helping people experience life's beautiful moments. Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year. Cooper operates through two business segments, CooperVision and CooperSurgical. Our two business segments elevate standards of care with products and services in the fields of vision, fertility and women's health. CooperVision is a global manufacturer providing products for contact lens wearers. CooperVision develops, manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. CooperVision designs its products to address vision challenges such as astigmatism, presbyopia and myopia with a broad collection of spherical, toric and multifocal contact lenses. CooperVision also manufactures and markets myopia management products, including the internally developed MiSight 1 day lens, as well as other specialty eyecare products such as orthokeratology (ortho-k) and scleral lenses. CooperSurgical offers a broad array of products and services focused on fertility and women's health. Our portfolio encompasses more than 600 products and services. Our medical devices are used in gynecology and obstetrics, including but not limited to surgical products, contraception and labor and delivery as well as cord blood and cord tissue storage services. Our fertility portfolio encompasses medical devices supporting the in vitro fertilization (IVF) process, egg and sperm donation, cryopreservation, and genomic services (including genetic testing). CooperSurgical has established its market presence and distribution system by developing products and acquiring companies, products and services that complement its business model.
Primary products
- Biofinity
- Biofinity Energys
- Avaira Vitality
- MyDay
- MyDay Energys
- clariti 1 day
Business segments
End markets
Geographies
Named competitors
“We believe that in order to compete successfully in the numerous categories of the contact lens market, companies must offer differentiated products that are priced competitively and manufactured efficiently.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
CooperVision net sales grew 5% year-over-year to $2,743.8 million and CooperSurgical net sales grew 5% to $1,348.6 million, driving consolidated net sales growth from $3,895.4 million in fiscal 2024 to $4,092.4 million in fiscal 2025.
The rest of COO is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.